A leading pharmaceutical giant has developed a drug, AZD1236 , that can significantly reduce secondary damage caused by the body’s response to spinal cord injuries . Researchers from the University of Birmingham used animal models to demonstrate the effects of this drug in the following manner: Effects of AZD1236 on receptors, bloodstream, and cerebrospinal fluid around the spinal cord following injury: Suppresses injury-induced edema, the activity of matrix metalloprotease (MMP)-9 and MMP-12 , proinflammatory pain markers, pain sensation, and blood-spinal cord barrier (BSCB) breakdown.
It also promotes axon regeneration, improving electrophysiological, sensory, and locomotor function. The findings of this study are published in Clinical and Translational Medicine and suggest that AZD1236 has the potential to be included as the first line of treatment following spinal cord injuries…
